Company Overview - Zhaoyan New Drug (SH 603127) announced the convening of its fifth board meeting on December 5, 2025, to discuss the appointment of the internal audit director and other documents [1] - As of the report date, Zhaoyan New Drug has a market capitalization of 20.9 billion yuan [1] Revenue Composition - For the year 2024, Zhaoyan New Drug's revenue composition is as follows: - Preclinical drug research services account for 95.0% - Clinical services account for 4.95% - Sales of laboratory animals and related products account for 0.04% [1]